The development of cancer immunotherapy is increasingly moving beyond broadly administered immune checkpoint blockade toward strategies designed around the molecular characteristics of an individual patient’s tumor.
A major milestone in this direction has now been reported.
On August 19, 2026, Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy, in combination with pembrolizumab as adjuvant treatment for patients with completely resected high-risk cutaneous melanoma.
The study met its primary endpoint of recurrence-free survival (RFS) and its key secondary endpoint of distant metastasis-free survival (DMFS), demonstrating statistically significant and clinically meaningful improvements with intismeran plus pembrolizumab compared with pembrolizumab alone.
According to the companies, this represents the first positive Phase 3 readout for an individualized neoantigen therapy and the first positive Phase 3 readout for an mRNA-based cancer therapy.
10 Ongoing Clinical Trials on Immunotherapy in Melanoma
What Is Intismeran Autogene?
Intismeran autogene, previously known as V940 or mRNA-4157, is an investigational individualized neoantigen therapy designed specifically for each patient.
Rather than targeting a predefined antigen shared across tumors, the therapy is developed using the unique mutational profile of an individual patient’s cancer.
The individualized mRNA construct can encode up to 34 neoantigens, selected on the basis of the patient’s tumor-specific mutational profile. The therapeutic objective is to generate immune responses directed against these tumor-associated neoantigens.
This represents an important conceptual difference from conventional anticancer therapies: the treatment itself is individualized according to the molecular features of each patient’s tumor.
Why Combine Intismeran With Pembrolizumab?
Intismeran is being developed in combination with pembrolizumab, an anti-PD-1 immune checkpoint inhibitor.
Pembrolizumab binds PD-1 and blocks its interaction with PD-L1 and PD-L2, thereby reducing PD-1-mediated inhibition of T-cell activity.
The combination therefore brings together two distinct immunotherapeutic approaches: an individualized therapy designed to generate immune responses against patient-specific tumor neoantigens and an established checkpoint inhibitor that blocks PD-1-mediated immune suppression.
The Phase 3 INTerpath-001 trial was designed to determine whether adding individualized neoantigen therapy to pembrolizumab could improve outcomes compared with pembrolizumab alone after complete surgical resection of high-risk melanoma.
The INTerpath-001 Phase 3 Trial
INTerpath-001 is a global, randomized, double-blind, placebo- and active-comparator-controlled Phase 3 trial.
The study enrolled 1,137 patients with completely resected stage IIB, IIC, III, or IV cutaneous melanoma who had not previously received systemic therapy for their disease.
Following complete surgical resection, patients were randomized 2:1 to receive intismeran plus pembrolizumab or pembrolizumab alone.
The investigational regimen consisted of:
- Intismeran 1 mg every 3 weeks for up to 9 doses
- Pembrolizumab 400 mg every 6 weeks for up to 9 cycles
Treatment could continue for approximately 56 weeks, or until disease recurrence or unacceptable toxicity.
The study’s primary endpoint was recurrence-free survival, defined as the time from randomization to local, locoregional, regional, or distant recurrence, or death from any cause.
Key secondary endpoints included distant metastasis-free survival, overall survival, safety, tolerability, and quality of life.
Phase 3 Results: RFS and DMFS Endpoints Were Met
At the prespecified interim analysis, INTerpath-001 met its primary endpoint.
The combination of intismeran plus pembrolizumab significantly improved recurrence-free survival compared with pembrolizumab alone.
The study also met the key secondary endpoint of distant metastasis-free survival, with the combination demonstrating a statistically significant and clinically meaningful improvement in DMFS.
These findings provide Phase 3 evidence that adding an individualized neoantigen therapy to PD-1 blockade can improve disease-control outcomes following complete resection of high-risk melanoma.
However, the currently available information remains a topline announcement.
The Phase 3 hazard ratios, confidence intervals, absolute RFS and DMFS rates, subgroup analyses, and detailed safety results have not yet been reported in the available announcement.
These data will therefore be essential for determining the magnitude and clinical context of the observed benefit.
Overall Survival Remains Under Evaluation
Overall survival is a key secondary endpoint of INTerpath-001, but the OS analysis is not yet mature. The trial is continuing according to protocol, and overall survival will continue to be evaluated.
This distinction is important.
The current Phase 3 result establishes a significant improvement in RFS and DMFS, but it does not yet demonstrate an overall survival benefit. Longer follow-up will therefore be required to determine whether the reduction in recurrence and distant metastasis ultimately translates into improved survival.
Building on the Phase 2b KEYNOTE-942 Results
The Phase 3 findings build on the earlier randomized Phase 2b KEYNOTE-942/mRNA-4157-P201 study, which evaluated intismeran plus pembrolizumab versus pembrolizumab alone in patients with resected high-risk melanoma.
Long-term follow-up from this study continued to demonstrate an advantage for the combination.
At five years, intismeran plus pembrolizumab was associated with:
- 49% reduction in the risk of recurrence or death, with an RFS HR of 0.51 (95% CI, 0.294–0.887)
- 59% reduction in the risk of distant metastasis or death, with a DMFS HR of 0.411 (95% CI, 0.200–0.843)
compared with pembrolizumab alone.
The positive INTerpath-001 result therefore represents an important progression from the earlier Phase 2b signal to a substantially larger randomized Phase 3 study.
What Do We Know About Safety?
According to the topline Phase 3 announcement, the safety profiles of intismeran and pembrolizumab were consistent with those previously observed, and no new safety signals were identified.
Detailed Phase 3 safety results have not yet been disclosed.
These data will be particularly important in the adjuvant setting, where patients have undergone complete surgical resection and treatment is intended to reduce the risk of future recurrence.
The eventual interpretation of INTerpath-001 will therefore require assessment not only of the relative improvement in RFS and DMFS, but also of absolute benefit, treatment-related toxicity, treatment discontinuation, quality of life, and longer-term safety.
Why INTerpath-001 Is Scientifically Important
The significance of INTerpath-001 extends beyond melanoma.
Immune checkpoint inhibitors are standardized therapies: patients receive the same antibody regardless of the individual neoantigen composition of their tumors.
Intismeran introduces a fundamentally different therapeutic principle.
The treatment is individualized according to the mutational profile of each patient’s tumor and can encode up to 34 patient-specific neoantigens.
The positive Phase 3 result therefore provides clinical validation, at the level of RFS and DMFS, of a strategy combining individualized neoantigen-directed immunotherapy with established PD-1 blockade.
It is important, however, not to extend the current findings beyond what the trial has demonstrated.
INTerpath-001 establishes efficacy endpoints in resected high-risk cutaneous melanoma. It does not yet establish that the same approach will be effective across other tumor types, nor does the currently available topline information identify which molecular or immunological characteristics predict benefit from the individualized therapy.
Beyond Melanoma: The INTerpath Development Program
Intismeran is being investigated beyond melanoma.
The broader INTerpath clinical development program includes nine Phase 2 and Phase 3 studies across melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma, with additional clinical investigation in pancreatic ductal adenocarcinoma, gastric cancer, and perioperative NSCLC.
The results of these studies will be important for determining whether individualized neoantigen therapy can become a broader immuno-oncology platform or whether its clinical activity will vary substantially according to tumor type and disease setting.
For now, the strongest evidence comes from melanoma, where the strategy has progressed from randomized Phase 2b activity to a positive Phase 3 trial.
What We Still Need to See
Despite the significance of the announcement, several clinically important questions cannot yet be answered.
The complete INTerpath-001 dataset is needed to determine the magnitude of the RFS and DMFS improvements, absolute event rates, consistency of benefit across disease stages and other clinically relevant subgroups, detailed toxicity, treatment discontinuation rates, and quality-of-life outcomes.
Overall survival also remains under evaluation.
Until these data are presented, the result should therefore be described precisely as a positive Phase 3 topline readout, rather than as evidence of a defined magnitude of survival benefit or a new standard of care.